| Literature DB >> 29221805 |
Judith Lorant1, Charlotte Saury2, Cindy Schleder1, Florence Robriquet3, Blandine Lieubeau4, Elisa Négroni5, Isabelle Leroux1, Lucie Chabrand6, Sabrina Viau6, Candice Babarit1, Mireille Ledevin1, Laurence Dubreil1, Antoine Hamel7, Armelle Magot8, Chantal Thorin9, Laëtitia Guevel3, Bruno Delorme6, Yann Péréon8, Gillian Butler-Browne5, Vincent Mouly5, Karl Rouger10.
Abstract
After intra-arterial delivery in the dystrophic dog, allogeneic muscle-derived stem cells, termed MuStem cells, contribute to long-term stabilization of the clinical status and preservation of the muscle regenerative process. However, it remains unknown whether the human counterpart could be identified, considering recent demonstrations of divergent features between species for several somatic stem cells. Here, we report that MuStem cells reside in human skeletal muscle and display a long-term ability to proliferate, allowing generation of a clinically relevant amount of cells. Cultured human MuStem (hMuStem) cells do not express hematopoietic, endothelial, or myo-endothelial cell markers and reproducibly correspond to a population of early myogenic-committed progenitors with a perivascular/mesenchymal phenotypic signature, revealing a blood vessel wall origin. Importantly, they exhibit both myogenesis in vitro and skeletal muscle regeneration after intramuscular delivery into immunodeficient host mice. Together, our findings provide new insights supporting the notion that hMuStem cells could represent an interesting therapeutic candidate for dystrophic patients.Entities:
Keywords: DMD; MuStem; cell therapy; human adult stem cells; regenerative medicine; skeletal muscle
Mesh:
Year: 2017 PMID: 29221805 PMCID: PMC5835152 DOI: 10.1016/j.ymthe.2017.10.013
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454